Work

Real‐World Treatment Escalation Patterns of Biologics and Functional Endoscopic Sinus Surgery in Chronic Rhinosinusitis (CRS): A Nationwide Database Study

Year: 2026

Type: article

Abstract: Key Points• FESS demonstrated durable 3-year outcomes, with 3.5% requiring biologic initiation and 5.7% requiring revision surgery.• Dupilumab had the lowest biologic switching rates; mepolizumab had the highest rates of switching and surgical escalation.• In the propensity-matched cohort, rates of biologic initiation after primary FESS were similar to rates of biologic switching in the biologics cohort at 36 months (5.6 vs. 5.4%).

Source: International Forum of Allergy & Rhinology

DOI: 10.1002/alr.70270

Authors: Omer Baker, Bita Naimi, Soraya Mehdipour, Adam S. Deconde, Carol H. Yan

Institutions: University of California San Diego, UC San Diego Health System

Language: English

Topic: Sinusitis and nasal conditions

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,100